Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials

Author(s): Dénes Kleiner, István László Horváth, Stefania Bunduc, Dorottya Gergő, Katalin Lugosi, Péter Fehérvári, Péter Hegyi and Dezső Csupor*

Volume 21, Issue 12, 2023

Published on: 31 July, 2023

Page: [2505 - 2515] Pages: 11

DOI: 10.2174/1570159X21666230727094431

Price: $65

conference banner
Abstract

Background: Spasticity affects 54% of multiple sclerosis (MS) patients at disease onset, but this rate gradually increases with disease progression. Spasticity does not fully respond to standard treatment in one-third of the patients.

Objective: Our systematic review and meta-analysis assessed whether add-on nabiximols, can improve MS-associated refractory spasticity.

Methods: The systematic literature search was performed in Web of Science, MEDLINE, Scopus, CENTRAL, and Embase, on 15/10/2021, without restrictions. We included in the review blinded, randomized, placebo-controlled trials evaluating the efficacy of nabiximols in adult MS patients with refractory spasticity, by comparison with placebo. The primary outcome was responder rate by spasticity numerical rating scale (NRS). Secondary outcomes were spasticity-related parameters. We used random effect models to calculate odds ratios (OR) or mean differences and the corresponding 95% CI. Bias-factors were assessed with Cochrane risk of bias tool (RoB2). (PROSPERO ID: CRD42021282177).

Results: We identified 9 eligible articles, of which 7 (1128 patients) were included in the meta-analysis. The spasticity numerical rating scale (NRS) was significantly higher in the nabiximols group than in the placebo group (OR 2.41 (95% CI 1.39; 4.18)). Secondary outcomes were in accordance with our primary results. At least some concerns were detected in the risk of bias analysis.

Conclusion: Our results indicate that nabiximols is efficient in MS associated spasticity, refractory to standard treatment and it may be considered as add-on symptomatic therapy. Nevertheless, further studies are needed to establish the optimal treatment protocol – dose, duration, moment of initiation, disease type.

« Previous Next »
Graphical Abstract

[1]
Walton, C.; King, R.; Rechtman, L.; Kaye, W.; Leray, E.; Marrie, R.A. 2020.
[http://dx.doi.org/10.1177/1352458520970841]
[2]
Fernández, Ó.; Costa-Frossard, L.; Martínez-Ginés, M.; Montero, P.; Prieto, J.M.; Ramió, L. The broad concept of “spasticity-plus syndrome” in multiple sclerosis: a possible new concept in the management of multiple sclerosis symptoms. Front. Neurol., 2020, 11, 152.
[http://dx.doi.org/10.3389/fneur.2020.00152] [PMID: 32256440]
[3]
D’hooghe, M.; Willekens, B.; Delvaux, V.; D’haeseleer, M.; Guillaume, D.; Laureys, G.; Nagels, G.; Vanderdonckt, P.; Van Pesch, V.; Popescu, V. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurol., 2021, 21(1), 227.
[http://dx.doi.org/10.1186/s12883-021-02246-0] [PMID: 34157999]
[4]
Pozzilli, C. Overview of MS Spasticity. Eur. Neurol., 2014, 71(Suppl. 1), 1-3.
[http://dx.doi.org/10.1159/000357739] [PMID: 24457845]
[5]
Hugos, C.L.; Cameron, M.H. Assessment and measurement of spasticity in MS: state of the evidence. Curr. Neurol. Neurosci. Rep., 2019, 19(10), 79.
[http://dx.doi.org/10.1007/s11910-019-0991-2] [PMID: 31471769]
[6]
Collin, C.; Davies, P.; Mutiboko, I.K.; Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol., 2007, 14(3), 290-296.
[http://dx.doi.org/10.1111/j.1468-1331.2006.01639.x] [PMID: 17355549]
[7]
Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; Schmidlkofer, S.; Westwood, M.; Kleijnen, J. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015, 313(24), 2456-2473.
[http://dx.doi.org/10.1001/jama.2015.6358] [PMID: 26103030]
[8]
Wade, D.T.; Collin, C.; Stott, C.; Duncombe, P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler., 2010, 16(6), 707-714.
[http://dx.doi.org/10.1177/1352458510367462] [PMID: 20558502]
[9]
GW pharma ltd. sativex oromucosal spray GW Pharma Ltd, Available From:https://www.medicines.org.uk/emc/product/602/smpc#gref(Accessed Jun 02, 2022)
[10]
Montalban, X.; Gold, R.; Thompson, A.J.; Otero-Romero, S.; Amato, M.P.; Chandraratna, D.; Clanet, M.; Comi, G.; Derfuss, T.; Fazekas, F.; Hartung, H.P.; Havrdova, E.; Hemmer, B.; Kappos, L.; Liblau, R.; Lubetzki, C.; Marcus, E.; Miller, D.H.; Olsson, T.; Pilling, S.; Selmaj, K.; Siva, A.; Sorensen, P.S.; Sormani, M.P.; Thalheim, C.; Wiendl, H.; Zipp, F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler., 2018, 24(2), 96-120.
[http://dx.doi.org/10.1177/1352458517751049] [PMID: 29353550]
[11]
Carod-Artal, F.J.; Adjamian, P.; Vila Silván, C.; Bagul, M.; Gasperini, C. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev. Neurother., 2022, 22(6), 499-511.
[http://dx.doi.org/10.1080/14737175.2022.2075263] [PMID: 35582858]
[12]
Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane, 2022.
[13]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372, n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[14]
Aydin, O.; Yassikaya, M.Y. Validity and reliability analysis of the plotdigitizer software program for data extraction from single-case graphs. Perspect. Behav. Sci., 2022, 45(1), 239-257.
[http://dx.doi.org/10.1007/s40614-021-00284-0] [PMID: 35342869]
[15]
Huwaldt, J.A. Plot digitizer 2.6.9. ed., Available from:http://plotdigitizer.sourceforge.net/2001
[16]
Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst., 1959, 22(4), 719-748.
[PMID: 13655060]
[17]
Robins, J.; Greenland, S.; Breslow, N. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am. J. Epidemiol., 1986, 124(5), 719-723.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a114447] [PMID: 3766505]
[18]
Paule, R.C.; Mandel, J. Concensus values and weighting factors. J. Res. Natl. Bur. Stand., 1982, 87(5), 377-385.
[http://dx.doi.org/10.6028/jres.087.022] [PMID: 34566088]
[19]
Harrer, M.; Pim, C.; Furukawa, T.A.; David, D.E. Doing Meta-Analysis With R: A Hands-On Guide; Chapman and Hall/CRC: Boca Raton, USA, 2021.
[http://dx.doi.org/10.1201/9781003107347]
[20]
Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21(11), 1539-1558.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[21]
Viechtbauer, W.; Cheung, M.W.L. Outlier and influence diagnostics for meta-analysis. Res. Synth. Methods, 2010, 1(2), 112-125.
[http://dx.doi.org/10.1002/jrsm.11] [PMID: 26061377]
[22]
R Core Team. A language and environment for statistical computing (version Foundation for Statistical Computing), Available from:https://www.R-project.org/2021
[23]
Wickham, H.; Averick, M.; Bryan, J.; Chang, W.; McGowan, L.; François, R.; Grolemund, G.; Hayes, A.; Henry, L.; Hester, J.; Kuhn, M.; Pedersen, T.; Miller, E.; Bache, S.; Müller, K.; Ooms, J.; Robinson, D.; Seidel, D.; Spinu, V.; Takahashi, K.; Vaughan, D.; Wilke, C.; Woo, K.; Yutani, H. Welcome to the tidyverse. J. Open Source Softw., 2019, 4(43), 1686.
[http://dx.doi.org/10.21105/joss.01686]
[24]
Balduzzi, S.; Rücker, G.; Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health, 2019, 22(4), 153-160.
[http://dx.doi.org/10.1136/ebmental-2019-300117] [PMID: 31563865]
[25]
Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw., 2010, 36(3), 1-48.
[http://dx.doi.org/10.18637/jss.v036.i03]
[26]
Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; Emberson, J.R.; Hernán, M.A.; Hopewell, S.; Hróbjartsson, A.; Junqueira, D.R.; Jüni, P.; Kirkham, J.J.; Lasserson, T.; Li, T.; McAleenan, A.; Reeves, B.C.; Shepperd, S.; Shrier, I.; Stewart, L.A.; Tilling, K.; White, I.R.; Whiting, P.F.; Higgins, J.P.T. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366, l4898.
[http://dx.doi.org/10.1136/bmj.l4898] [PMID: 31462531]
[27]
GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Grou,, 2013.
[28]
GRADEpro GDT: GRADEpro guideline development tool., 2021.
[29]
Nct. A study of sativex® for relief of spasticity in subjects with multiple sclerosis. Clinicaltrials gov, national institutes of health., https://clinicaltrials.gov/ct2/show/results/NCT007116462008(Accessed Jun 02, 2022)
[30]
Nct. A study to evaluate the efficacy of sativex in relieving symptoms of spasticity due to multiple sclerosis. 2012. (Accessed Jun 02, 2022)
[31]
Nct. A study of the safety and effectiveness of sativex®, for the relief of symptoms of spasticity in subjects with multiple sclerosis (MS). https://clinicaltrials.gov/ct2/show/NCT006815382010(Accessed Jun 02, 2022)
[32]
Euctr, I.T. Clinical study to evaluate the effectiveness of sativex in relieving pain people affected by multiple sclerosis., https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002258-30/results2012(Accessed Jun 02, 2022)
[33]
Euctr, A.T. Sativex® as add-on therapy vs. further optimized firstline antispastics., 2016. https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004451-40/results(Accessed Jun 02, 2022)
[34]
Wade, D.T.; Makela, P.; Robson, P.; House, H.; Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler., 2004, 10(4), 434-441.
[http://dx.doi.org/10.1191/1352458504ms1082oa] [PMID: 15327042]
[35]
Aragona, M.; Onesti, E.; Tomassini, V.; Conte, A.; Gupta, S.; Gilio, F.; Pantano, P.; Pozzilli, C.; Inghilleri, M. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol., 2009, 32(1), 41-47.
[http://dx.doi.org/10.1097/WNF.0b013e3181633497] [PMID: 18978501]
[36]
Collin, C.; Ehler, E.; Waberzinek, G.; Alsindi, Z.; Davies, P.; Powell, K.; Notcutt, W.; O’Leary, C.; Ratcliffe, S.; Nováková, I.; Zapletalova, O.; Piková, J.; Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res., 2010, 32(5), 451-459.
[http://dx.doi.org/10.1179/016164109X12590518685660] [PMID: 20307378]
[37]
Novotna, A.; Mares, J.; Ratcliffe, S.; Novakova, I.; Vachova, M.; Zapletalova, O.; Gasperini, C.; Pozzilli, C.; Cefaro, L.; Comi, G.; Rossi, P.; Ambler, Z.; Stelmasiak, Z.; Erdmann, A.; Montalban, X.; Klimek, A.; Davies, P. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol., 2011, 18(9), 1122-1131.
[http://dx.doi.org/10.1111/j.1468-1331.2010.03328.x] [PMID: 21362108]
[38]
Leocani, L.; Nuara, A.; Houdayer, E.; Schiavetti, I.; Del Carro, U.; Amadio, S.; Straffi, L.; Rossi, P.; Martinelli, V.; Vila, C.; Sormani, M.P.; Comi, G. Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. J. Neurol., 2015, 262(11), 2520-2527.
[http://dx.doi.org/10.1007/s00415-015-7878-1] [PMID: 26289497]
[39]
Markovà, J.; Essner, U.; Akmaz, B.; Marinelli, M.; Trompke, C.; Lentschat, A.; Vila, C. Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int. J. Neurosci., 2019, 129(2), 119-128.
[http://dx.doi.org/10.1080/00207454.2018.1481066] [PMID: 29792372]
[40]
Langford, R.M.; Mares, J.; Novotna, A.; Vachova, M.; Novakova, I.; Notcutt, W.; Ratcliffe, S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol., 2013, 260(4), 984-997.
[http://dx.doi.org/10.1007/s00415-012-6739-4] [PMID: 23180178]
[41]
Conte, A.; Bettolo, C.M.; Onesti, E.; Frasca, V.; Iacovelli, E.; Gilio, F.; Giacomelli, E.; Gabriele, M.; Aragona, M.; Tomassini, V.; Pantano, P.; Pozzilli, C.; Inghilleri, M. Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. Eur. J. Pain, 2009, 13(5), 472-477.
[http://dx.doi.org/10.1016/j.ejpain.2008.05.014] [PMID: 18603457]
[42]
Symptom management of multiple sclerosis in adults. 2022. Available from:https://www.uptodate.com/contents/symptom-management-of-multiple-sclerosis-in-adults?search = spasticity%20multiple%20 sclerosis&source = search_result&selectedTitle = 1~150&usage_type = default&display_rank = 1(Accessed May 30, 2022)
[43]
Nielsen, S.; Murnion, B.; Campbell, G.; Young, H.; Hall, W. Cannabinoids for the treatment of spasticity. Dev. Med. Child Neurol., 2019, 61(6), 631-638.
[http://dx.doi.org/10.1111/dmcn.14165] [PMID: 30680713]
[44]
Patti, F.; Chisari, C.G.; Solaro, C.; Benedetti, M.D.; Berra, E.; Bianco, A.; Bruno, B.R.; Buttari, F.; Castelli, L.; Cavalla, P.; Cerqua, R.; Costantino, G.; Gasperini, C.; Guareschi, A.; Ippolito, D.; Lanzillo, R.; Maniscalco, G.T.; Matta, M.; Paolicelli, D.; Petrucci, L.; Pontecorvo, S.; Righini, I.; Russo, M.; Saccà, F.; Salamone, G.; Signoriello, E.; Spinicci, G.; Spitaleri, D.; Tavazzi, E.; Trotta, M.; Zaffaroni, M.; Zappia, M. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurol. Sci., 2020, 41(10), 2905-2913.
[http://dx.doi.org/10.1007/s10072-020-04413-6] [PMID: 32335779]
[45]
Flachenecker, P.; Henze, T.; Zettl, U.K. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur. Neurol., 2014, 71(5-6), 271-279.
[http://dx.doi.org/10.1159/000357427] [PMID: 24525548]
[46]
Vermersch, P.; Trojano, M. Tetrahydrocannabinol: Cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. Eur. Neurol., 2016, 76(5-6), 216-226.
[http://dx.doi.org/10.1159/000449413] [PMID: 27732980]
[47]
Mahoney, F.I.; Barthel, D.W. Functional evaluation: the barthel index. Md. State Med. J., 1965, 14, 61-65.
[PMID: 14258950]
[48]
Carotenuto, A.; Costabile, T.; De Lucia, M.; Moccia, M.; Falco, F.; Petruzzo, M.; De Angelis, M.; Russo, C.V.; Saccà, F.; Lanzillo, R.; Brescia, M.V. Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. J. Neurol., 2020, 267(6), 1737-1743.
[http://dx.doi.org/10.1007/s00415-020-09739-x] [PMID: 32124041]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy